Patent
Cell impregnated sleeve for paracrine and other factor production
| العنوان: | Cell impregnated sleeve for paracrine and other factor production |
|---|---|
| Patent Number: | 10561,830 |
| تاريخ النشر: | February 18, 2020 |
| Appl. No: | 15/025902 |
| Application Filed: | October 07, 2014 |
| مستخلص: | Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly. |
| Inventors: | THE JOHNS HOPKINS UNIVERSITY (Baltimore, MD, US); Hwang, Chao-Wei (West Friendship, MD, US); Xia, Zhiyong (Rockville, MD, US); Bogdan, Virginia E. (Owings Mills, MD, US); Brinker, Jeffrey A. (Baltimore, MD, US); Gerstenblith, Gary (Reisterstown, MD, US); Johnston, Peter V. (Baltimore, MD, US); Schulman, Steven P. (Baltimore, MD, US); Tomaselli, Gordon (Baltimore, MD, US); Weiss, Robert G. (Cockeysville, MD, US) |
| Assignees: | The Johns Hopkins University (Baltimore, MD, US) |
| Claim: | 1. A therapeutic sleeve device configured to be wrapped around an object and inserted into a subject, the therapeutic sleeve device comprising: (a) a nonwoven fiber fabric assembly defining a plurality of pores, wherein said nonwoven fiber fabric assembly comprises a nanofiber fabric assembly comprising at least one of poly(lactic acid), poly(L-lactic acid), poly(lactic-co- glycolic acid) copolymer, polycaprolactone, or polyethylene terephthalate; and (b) a plurality of stem cells, each stem cell of the plurality of stem cells embedded in one of the plurality of pores of the nonwoven fiber fabric assembly, wherein each stem cell of the plurality of stem cells is configured to emit paracrine factors, the paracrine factors being configured to promote healing of a tissue, organ, or wound of the subject, wherein each stem cell of the plurality of stem cells has a cell diameter, wherein each pore of the plurality of pores has a maximal pore size of less than 10 microns in diameter, wherein the maximal pore size of each pore is less than the cell diameter to form a cage inside which any of the plurality of stem cells is embedded and retained thereby configuring the cage to prevent interaction between cells of the subject and the plurality of stem cells in response to the therapeutic sleeve device being inserted into the subject, and wherein the maximal pore size is larger than a diameter of the paracrine factors emitted by each stem cell of the plurality of stem cells to allow for the paracrine factors to be emitted through the cage while the cage prevents washout and dilution of the plurality of stem cells from the therapeutic sleeve. |
| Claim: | 2. The therapeutic sleeve device according to claim 1 , wherein the nonwoven fiber fabric assembly comprises a first nonwoven fiber fabric layer and a second nonwoven fiber fabric layer and the plurality of stem cells are embedded between the first nonwoven fiber fabric layer and the second nonwoven fiber fabric layer. |
| Claim: | 3. The therapeutic sleeve device according to claim 1 , wherein the stem cells are mesenchymal stem cells. |
| Claim: | 4. The therapeutic sleeve device according to claim 1 , wherein the maximal pore size is less than cell diameters of the cells of the subject. |
| Claim: | 5. The therapeutic sleeve device according to claim 4 , wherein the cells of the subject comprise host immune cells. |
| Claim: | 6. The therapeutic sleeve device according to claim 1 , wherein an average pore size is greater than embedded cell product, nutrient, or waste diameters. |
| Claim: | 7. The therapeutic sleeve device according to claim 6 , wherein the average pore size is greater than about 100 nanometers, the cell diameter is about 20 microns, and paracrine factor diameters are less than 100 nanometers. |
| Claim: | 8. The therapeutic sleeve device according to claim 6 , wherein the average pore size is greater than about 300 nanometers, the cell diameter is about 20 microns, and exosome diameters are about 300 nanometers. |
| Claim: | 9. The therapeutic sleeve device according to claim 1 , wherein the nanofiber fabric assembly further comprises at least one of collagen, peptides, proteins, nucleic acids, fatty acids, gelatin, chitosan, or hyaluronic acid. |
| Claim: | 10. The therapeutic sleeve device according to claim 1 , further comprising at least one layer of adhesion molecules. |
| Claim: | 11. The therapeutic sleeve device according to claim 10 , wherein the adhesion molecules comprise at least one of fibronectin, fibrinogen, laminins, collagen, vitronectin, proteoglycans, arginyl-glycyl-aspartic (RGD) acid peptides, or cell specific antibodies. |
| Claim: | 12. The therapeutic sleeve device according to claim 11 , wherein the cell specific antibodies comprise anti-CD29 antibody. |
| Claim: | 13. The therapeutic sleeve device according to claim 1 , further comprising at least one layer of an antithrombotic material. |
| Claim: | 14. The therapeutic sleeve device according to claim 13 , wherein the antithrombotic material comprises at least one of an anticoagulant or an anti-platelet agent. |
| Patent References Cited: | 7972616 July 2011 Dubrow et al. 8303972 November 2012 Michal 8403980 March 2013 Wachter et al. 8518431 August 2013 Spedden et al. 2007/0041952 February 2007 Guilak et al. 2007/0269481 November 2007 Li et al. 2008/0077222 March 2008 Johnson et al. 2008/0083617 April 2008 Simpson et al. 2009/0018643 January 2009 Hashi et al. 2009/0091065 April 2009 Katti et al. 2010/0233234 September 2010 Arinzeh et al. 2011/0229551 September 2011 Doshi et al. 2011/0230411 September 2011 Zussman et al. 2011/0268776 November 2011 Schapira et al. 2011/0280912 November 2011 Langer et al. 2012/0083767 April 2012 Gerstenblith et al. 2013/0138155 May 2013 Hoornaert et al. 2013/0172988 July 2013 Kutryk et al. 2015/0335788 November 2015 Xia et al. 2006/069349 June 2006 |
| Other References: | Nagaya N. et al., “Transplantation of Mesenchymal Stem Cells Improves Cardiac Function in a Rat Model of Dilated Cardiomyopathy”, Circulation, 2005, vol. 112, pp. 1128-1135. (Year: 2005). cited by examiner Li W-J. et al., “Fabrication and Application of Nanofibrous Scaffolds in Tissue Engineering”, Curr Protoc. Cell Biol., Author manuscript; available in PMC 2010, Jan. 18 (Total pp. 1-15). (Year: 2010). cited by examiner Kam P. C. A.. et al., “Platelet Glycoprotein llb/llla Antagonists, Pharmacology and Clinical Developments”, Anesthesiology, 2002; vol. 96, pp. 1237-1249. (Year: 2002). cited by examiner Satori C.P. et al., “Bioanalysis of eukaryotic organelles”, Chem. Rev., Apr. 10, 2013, vol. 113, No. 4, pp. 2733-2811, attached as Author Manuscript available in PMC, total pp. 1-163 (Year: 2013). cited by examiner WIPO, Written Opinion of the International Searching Authority, PCT/US2014/059400, dated Jan. 16, 2015, pp. 1-4. cited by applicant WIPO, International Search Report, PCT/US2014/059400, dated Jan. 16, 2015, pp. 1-2. cited by applicant Kolambkar, Yash M., “Electrospun Nanofiber Meshes for the Functional Repair of Bone Defects,” Dissertation, Georgia Institute of Technology, Dec. 2009, pp. 1-216. cited by applicant F. Duttenhoefer, et al., “3D Scaffolds Co-Seeded With Human Endothelial Progenitor and Mesenchymal Stem Cells: Evidence of Prevascularisation '\vithin 7 Days,” European Cells and Materials, 2013, pp. 49-65. cited by applicant Thermofischer, Useful Numbers for Cell Culture, pp. 1-2, downloaded Aug. 5, 2019. cited by applicant |
| Primary Examiner: | Singh, Satyendra K |
| Attorney, Agent or Firm: | Hayward, Noah J. |
| رقم الانضمام: | edspgr.10561830 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |